anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is directed to the use of bcl-2 antisensc ohgomers to treal and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliterative related disorders. In one embodiment of the invention, a bcl-2 antiscnsc oligomer is administered ai high doses. The present invention is also directed to it method of preventing or treating a bcl'2 related disorder, in particular cancer comprising administering a bcl-2 antisense oligomcr for short periods of time. The present invention is further drawn to the use of bcl-2 amisense oligomers to increase the sensitiviiy of a subjeci to cancer therapeutics. The present invention also relates to pharmaceutical commissions comprising one or more bcl-2 amisense oligomers. which may comprise one or more cancer therapeutic agents.
Nasopharyngeal carcinoma (NPC) is a malignant tumor with high metastatic features originating from the nasopharynx. However, the underlying mechanism of Suppressor of variegation 3-9 homolog 2 (SUV39H2) in NPC remains poorly understood. RT-qPCR was carried out to examine SUV39H2 and SIRT1 expression in NPC tissues and cells. Kaplan-Meier method was utilized to evaluate the association between SUV39H2 level and overall survival. The function of SUV39H2 and SIRT1 in NPC cell viability, metastasis, and apoptosis was tested through CCK-8, transwell, and flow cytometry experiments. Here, it was uncovered that SUV39H2 level was augmented in NPC tissues and cells. Moreover, SUV39H2 expedited NPC cell viability, metastasis, and inhibited apoptosis, while SIRT1 addition reversed these impacts. Besides, SUV39H2 induced H3K9me3 enhancement to repress SIRT1 transcription via binding to SIRT1 promoter. Collectively, our results demonstrated upregulated SUV39H2 aggravated NPC tumorigenesis through SIRT1, which may offer a potential therapeutic target for NPC.
Effective and safe use of PROAIR HFA Inhalation Aerosol includes an understanding of the way that it should be administered.

Shake well before each spray.

Use PROAIR HFA Inhalation Aerosol only with the actuator supplied with the product. Discard the PROAIR HFA inhaler when the dose counter displays 0 or after the expiration date on the product, whichever comes first. Never immerse the canister in water to determine how full the canister is ("float test").

In general, the technique for administering PROAIR HFA Inhalation Aerosol to children is similar to that for adults. Children should use PROAIR HFA Inhalation Aerosol under adult supervision, as instructed by the patient's physician .
There is an increased risk for hallucinations and psychosis in patients taking VYALEV. In Study 1 [see Clinical Studies (14)], hallucinations occurred in 12.2% of patients treated with VYALEV compared to 1.5% of patients treated with oral immediate-release carbidopa-levodopa. Psychosis occurred in 4.1% of patients treated with VYALEV compared to 1.5% of patients treated with oral immediate-release carbidopa-levodopa. Treatment with VYALEV was discontinued in 1 (1.4%) patient because of hallucinations.

Hallucinations associated with levodopa may present shortly after the initiation of therapy and may be responsive to dose reduction of VYALEV or other concomitantly administered medications. Confusion, insomnia, and excessive dreaming may accompany hallucinations. Abnormal thinking and behavior may present with one or more symptoms, including paranoid ideation, delusions, hallucinations, confusion, psychosis, disorientation, aggressive behavior, agitation, and delirium. Review of treatment is recommended if these symptoms develop.

Because of the risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with VYALEV. In addition, medications that antagonize the effects of dopamine used to treat psychosis may exacerbate the symptoms of PD and may decrease the effectiveness of VYALEV [see Drug Interactions (7.3)].
Devices are provided for the controlled delivery of a therapeutic to a targeted location within a body. More particularly, devices are provided for controlling the rate of passage of an orally administered pill through a body, as well as for controlling the delivery of a therapeutic within the pill at a specific location within the body. Various types of devices, generally referred to herein as "catchers," are provided that can actively catch a pill as it passes through a body. The catcher can hold the pill at a specific location within the body until a predetermined event occurs, such as partial or complete administration of a therapeutic within the pill. The catcher can then release the pill upon command and/or upon the occurrence of the predetermined event to allow the pill to pass out of the body. In other embodiments, various types of pills are provided that can actively engage a catcher and remain engaged with the catcher until a predetermined event occurs.
Intrinsic plasticity, a fundamental process enabling neurons to modify their intrinsic properties, plays a crucial role in shaping neuronal input-output function and is implicated in various neurological and psychiatric disorders. Despite its importance, the underlying molecular mechanisms of intrinsic plasticity remain poorly understood. In this study, a new ubiquitin ligase adaptor, protein tyrosine phosphatase receptor type N (PTPRN), is identified as a regulator of intrinsic neuronal excitability in the context of temporal lobe epilepsy. PTPRN recruits the NEDD4 Like E3 Ubiquitin Protein Ligase (NEDD4L) to NaV1.2 sodium channels, facilitating NEDD4L-mediated ubiquitination, and endocytosis of NaV1.2. Knockout of PTPRN in hippocampal granule cells leads to augmented NaV1.2-mediated sodium currents and higher intrinsic excitability, resulting in increased seizure susceptibility in transgenic mice. Conversely, adeno-associated virus-mediated delivery of PTPRN in the dentate gyrus region decreases intrinsic excitability and reduces seizure susceptibility. Moreover, the present findings indicate that PTPRN exerts a selective modulation effect on voltage-gated sodium channels. Collectively, PTPRN plays a significant role in regulating intrinsic excitability and seizure susceptibility, suggesting a potential strategy for precise modulation of NaV1.2 channels' function.
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available. All patients must have failed at least two prior lines of conventional systemic therapy that must also include an approved CD20 based treatment. All patients will need to have CD20-positive disease, as determined by the expression of CD20 on tumor cells assayed within 6 months prior to study entry.

The study will consist of 2 parts, Part A and Part B. In Part A of the study, dose escalation will proceed according to the guidelines in the Treatment and Dosing section below, following a rule-based design methodology. Two different schedules will be explored to establish the PK profile and thus better inform the selection of the final dosing schedule to be developed. Arm A will explore a continuous weekly dosing schedule and will commence first. Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks. Part B dose expansion of the study will commence, in which a single dosing schedule will be explored in CD20-positive patients. The schedule will be selected based on PK and safety determinants from Study Part A.
The present invention provides a new simple polymeric matrix tablet that delivers highly soluble drugs over long periods of time and is easy to manufacture. More specifically, the drug is first granulated with or encapsulated in a swellable polymer, such as a gum, to form a granule. This granule is disposed in a matrix of a more swellable, erodible polymer, such as HPMC or Polyethyleneoxide, and optionally includes pectin. The more swellable erodible polymer has a diffusion rate coefficient which is greater than the diffusion rate coefficient of the relatively less swellable polymer. It is this difference in diffusion rate coefficients between the first and second polymers which controls the rate of drug release and allows the system to approach zero order drug delivery over the drug release period. Other advantages which the present invention holds over existing systems including ease of manufacturing and reproducibility of release profiles under well defined hydrodynamic conditions. The delivery system of the present invention has a potential to maximally release its drug content in a controlled manner over a long time period while achieving complete dissolution.
TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
BACKGROUND: Repair of thoracic aortic aneurysms with either endovascular repair (TEVAR) or open surgical repair (OSR) represents major surgery, is costly and associated with significant complications. The aim of this study was to establish accurate costs of delivering TEVAR and OSR in a cohort of UK NHS patients suitable for open and endovascular treatment for the whole treatment pathway from admission and to discharge and 12-month follow-up.
METHODS: A prospective study of UK NHS patients from 30 NHS vascular/cardiothoracic units in England aged ≥18, with distal arch/descending thoracic aortic aneurysms (CTAA) was undertaken. A multicentre prospective cost analysis of patients (recruited March 2014-July 2018, follow-up until July 2019) undergoing TEVAR or OSR was performed. Patients deemed suitable for open or endovascular repair were included in this study. A micro-costing approach was adopted.
RESULTS: Some 115 patients having undergone TEVAR and 35 patients with OSR were identified. The mean (s.d.) cost of a TEVAR procedure was higher £26 536 (£9877) versus OSR £17 239 (£8043). Postoperative costs until discharge were lower for TEVAR £7484 (£7848) versus OSR £28 636 (£23 083). Therefore, total NHS costs from admission to discharge were lower for TEVAR £34 020 (£14 301), versus OSR £45 875 (£43 023). However, mean NHS costs for 12 months following the procedure were slightly higher for the TEVAR £5206 (£11 585) versus OSR £5039 (£11 994).
CONCLUSIONS: Surgical procedure costs were higher for TEVAR due to device costs. Total in-hospital costs were higher for OSR due to longer hospital and critical care stay. Follow-up costs over 12 months were slightly higher for TEVAR due to hospital readmissions.
POLYPEPTIDE CARTILAGE-INDUCING     FACTORS FOUND IN BONE                            Abstract Two polypeptide factors that are found in bone and that have chondrogenic/osteogenic activity and TGF-activity are described.  Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE.  Each reduces to a single polypeptide indicating that the factors are probably homodimers.  One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta., whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta.  The two factors are purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with genetic susceptibility. It is characterized by chronic synovitis and progressive joint destruction. There is synovial infiltration by inflammatory cells, activation of synovial fibroblasts, and production of a wide range of inflammatory cytokines. Sustained high disease activity results in a poor disease outcome so assessment of inflammatory activity in RA is of pivotal importance for the optimal treatment in these patients. Disease activity of RA patients is assessed by clinical examination, laboratory tests and radiographic assessment (e.g. ultrasonography). Laboratory assessment of RA activity is done routinely by measuring acute phase reactants such as an erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), which are elevated in most patients with RA. It has been demonstrated that more than 40% of RA patients have normal ESR or CRP (false negative results). Therefore, new serum markers that can more accurately reflect real inflammatory activity in RA patients are needed. Calprotectin (CLP) is a calcium binding leucocyte protein consisting of the heterocomplex of S100A8/ A9 (myeloid-related protein, MRP8/MRP14), as well as being a major monocyte/macrophage protein which has gained interest as a marker of inflammation in RA. Calprotectin has been identified as an important endogenous alarmin, one of the damage-associated molecular pattern (DAMP) molecules that acts as a ligand for the TLR4 receptor and amplifies the inflammation cascade via NF-kB and p38 mitogen-activated protein kinase. Calprotectin levels are higher in the serum of RA patients compared with healthy subjects or patients with osteoarthritis (OA), Still, no cut-off levels have been identified to help in the diagnosis of RA. Calprotectin is involved in cartilage damage in OA. Synovial lining macrophages play a role in the OA process and in cartilage damage. Moderate calprotectin increase has been observed in the serum of OA patients compared with healthy controls also serum calprotectin levels were found higher in OA patients with synovial inflammation compared with those without.
The illustrative embodiments described herein provide a computer implemented method, apparatus, and computer program product for generating never-event cohorts. In response to receiving patient care data derived from a population of patients, the patient care data is processed to form digital patient care data. The digital patient care data includes metadata describing a set of patient care patterns associated with one or more patients in the population of patients. The digital patient care data is analyzed using cohort criteria to identify a set of never-event attributes from the set of patient care patterns. The cohort criteria specifies at least one never-event attribute from the set of never-event attributes for each cohort in a set of never-event cohorts. Thereafter, a set of never-event cohorts is generated. The set of never-event cohorts is formed from members selected from the population of patients, and each member of a cohort in the set of never-event cohorts has the at least one never-event attribute in common.
TRAIL is a 4-week progressive exercise and self-management intervention for lower extremity recovery delivered by a trained registered physical therapist, in a 2:1 participant-to-therapist ratio. Each participant grouping will receive two telerehabilitation sessions (60-90 minutes) each week for 4 weeks (total 8-12 hours).
INTRODUCTION: Adolescents with functional (nonepileptic) seizures experience challenges self-managing this mental health condition, especially at school where adolescents experience stress, bullying, accusations of faking seizures, and stigma. According to the Common Sense Model of Self-Regulation, adolescents' self-management decisions and outcomes may be shaped by their functional seizure illness representation (perceptions or mental depictions formed in response to a health threat). However, current research has only explored adults' functional seizure illness representation; little is known about adolescents. The aim of this study was to explore adolescents' expressions of illness representation characteristics (identity, cause, consequence, controllability/curability, and timeline) when describing their experience attending school with functional seizures.
METHODS: We analyzed qualitative data from 10 adolescents (age 12-19 years, 100% female) from the United States with functional seizures. Data collection occurred in 2019 via semistructured interviews about adolescents' school experiences. The theme of illness representation emerged without prompting adolescents to discuss illness representation or its characteristics. This study involved inductive analyses and magnitude coding of adolescents' unsolicited expressions of illness representation.
RESULTS: All five characteristics of illness representation were mentioned by adolescents; however, not all characteristics were mentioned by all adolescents. Adolescents' expressions of illness representation characteristics resulted in the following descriptive themes: clashing labels and mind-body façade for identity, stress for cause, gains and losses for consequence, control/lack of control for controllability/curability, and no end of seizures in sight for timeline.
CONCLUSIONS: Adolescents' expressions of illness representation reveal perceptions considered "threatening" within the Common Sense Model, especially those expressing lack of controllability/curability and condition timelines with no end in sight. The Common Sense Model offers a framework for understanding how these threatening perceptions may impact health and academic outcomes or change with intervention.
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV). The vast majority will have been infected with HCV, and approximately 1/3 will have been infected with human immunodeficiency virus (HIV). Primary objectives are to quantify the rates of liver decompensation, hepatocellular carcinoma, and non-Hodgkin lymphoma and to evaluate candidate clinical, genetic, virologic, serologic and immunologic markers that are likely to be on the causal pathway for these conditions. Candidate clinical and laboratory markers will be examined longitudinally to define changes over time and their relationships to one another. Collaborative studies will focus on genome scanning and evaluation of candidate genetic loci for susceptibility or resistance to HCV and HIV infections or to the diseases that result from these infections. Additional studies will identify response and complication rates of various anti-HCV and anti-HIV regimens in the setting of comprehensive clinical care of persons with hemophilia.
The invention discloses a quality detection method of Eleutherine plicata Herb and an extract of the Eleutherine plicata Herb. The method comprises character identification of the Eleutherine plicata Herb, thin-layer chromatography of the Eleutherine plicata Herb and the extract of the Eleutherine plicata Herb, and content detection of total flavones and total anthraquinones. The quality detection method comprises specific steps as follows: (1) the characters: illustrating the characters, the colors, the size and the smell of the Eleutherine plicata Herb; (2) the thin-layer chromatography: extracting different polar parts of the medicinal material and extract thereof, and expanding the polar parts on a silica gel plate by using different development systems; and (3) the content detection: detecting the content of the total flavones and the total anthraquinones in the Eleutherine plicata Herb and the extract of the Eleutherine plicata Herb. According to the method disclosed by the invention, based on ultraviolet spectrophotometry, rutin and rhein are respectively used as a reference substance, and the Eleutherine plicata Herb or the extract of the Eleutherine plicata Herb is used as a test sample to detect the content of the test sample. The method disclosed by the invention has the advantages that the method is convenient and quick, the pertinence of the detection method is powerful, the precision, the stability and the repeatability are good, and the accuracy is high. And the method is applicable to the quality control of medicinal materials or the extract of the medicinal materials.
PURPOSE:A composition for lipsticks, containing a nut oil of macadamia and a cholesteryl-21-hydroxystearate, having soft and smooth feeling of use and good feeling of fit to the lips, improved keeping quality, preventing the roughness of the lips, and capable of giving moisture and luster to the lips. CONSTITUTION:A composition of lipsticks containing 25-70wt% nut oil of macadamia and 0.3-15wt% ester of cholesterol with 12-hydroxystearic acid expressed by the formula (n is 1,2 or 3). The use of the nut oil of the macadamia as a liquid oil component provides improved compatibility with other components, and lipsticks having a soft touch are obtained. The combination of the above-mentioned ester with the nut oil of the macadamia achieves the other purposes, e.g. improved feeling of fit to the lips. The nut oil of the macadamia is preferably a decolored and deodorized purified oil, and contains about 0.002- 0.2wt% antioxidant, e.g. tocopherol.
Numerous studies have confirmed that perineural dexamethasone prolongs bupivacaine and ropivacaine brachial plexus blocks by approximately 10 hours (from approx. 12 to 22 hours) without clinical evidence of toxicity. However, perineural toxicity in an animal model has raised concern about its use as a peripheral nerve block adjuvant. Moreover, recent studies suggest that high dose IV dexamethasone (810mg) prolongs analgesia to a similar degree as perineural dexamethasone for interscalene, supraclavicular and sciatic nerve blocks performed with ropivacaine and bupivacaine. However these studies only utilized fixed, high level doses of IV dexamethasone. Moreover, there remains a concern that high dose IV dexamethasone may lead to postoperative hyperglycemia and could possibly increase the risk of postoperative wound infection. Open surgery under general anesthesia has been shown to increase blood glucose levels with a peak at approximately 2 hours post-induction and results have been conflicting regarding whether or not IV dexamethasone causes greater increase. To the investigators' knowledge, it is not yet known if arthroscopic surgery under regional anesthesia triggers a similar increase in blood glucose levels and if this is impacted by administration of IV dexamethasone. The investigators aim to identify the duration of supraclavicular block prolongation that can be expected over a range of doses of IV dexamethasone. The investigators also seek to identify what association, if any, is noted between IV dexamethasone and changes in blood glucose levels after shoulder surgery with regional anesthesia and sedation. Finally, the investigators will collect data on side effects and postoperative complications, if any, in patients receiving a range of doses of IV dexamethasone.
The invention relates to an oral liquid used for resisting aging. The oral liquid is prepared from traditional Chinese medicines of prepared fleeceflower root, epimedium, prepared Siberian solomonseal rhizome, medlar, Mongolian milkvetch root, and salvia miltiorrhiza of different parts by weight. The invention also relates to a preparation method and a quality controlling method of the oral liquid. The oral liquid provided by the invention provides functions of vital energy benefiting, blood nourishing, and liver and kidney nourishing. With the oral liquid, climacteric syndrome, neurasthenia, and chronic fatigue syndrome can be treated. The oral liquid can also be used for treating phenomena of senility and physical weakness, lethargy, insomnia, amnesia, dim eyesight, deafness, and early-canities caused by insufficiency of vital energy and blood and deficiency of liver and kidney. As a result of acute toxicity tests, no obvious adverse reaction is caused by the oral liquid. Therefore, the preparation is a safe and effective Chinese patent medicine which is suitable to be clinically applied and popularized.